AlphaCore Capital LLC Boosts Stake in Sanofi $SNY

AlphaCore Capital LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 441.9% during the third quarter, Holdings Channel.com reports. The fund owned 15,234 shares of the company’s stock after buying an additional 12,423 shares during the quarter. AlphaCore Capital LLC’s holdings in Sanofi were worth $719,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Waterfront Wealth Inc. grew its holdings in shares of Sanofi by 0.4% during the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after purchasing an additional 214 shares in the last quarter. HighPoint Advisor Group LLC grew its stake in Sanofi by 2.3% in the 3rd quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after buying an additional 226 shares in the last quarter. HM Payson & Co. increased its holdings in shares of Sanofi by 3.4% in the 3rd quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after buying an additional 235 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its position in shares of Sanofi by 4.7% during the 3rd quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock valued at $252,000 after buying an additional 238 shares in the last quarter. Finally, CreativeOne Wealth LLC lifted its holdings in shares of Sanofi by 2.8% during the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock worth $434,000 after acquiring an additional 241 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 0.6%

NASDAQ SNY opened at $48.66 on Friday. The stock has a market cap of $118.68 billion, a P/E ratio of 13.52, a price-to-earnings-growth ratio of 1.25 and a beta of 0.45. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The stock has a 50 day simple moving average of $47.54 and a two-hundred day simple moving average of $48.58. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.